- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | CAMP4 verstärkt Verwaltungsrat mit Finanzexperte Michael MacLean | 3 | Investing.com Deutsch | ||
| Di | CAMP4 Therapeutics appoints Michael MacLean to board of directors | 2 | Investing.com | ||
| Di | CAMP4 Therapeutics: CAMP4 Appoints Michael MacLean to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| Di | Camp4 Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 06.03. | Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target | 4 | Investing.com | ||
| 05.03. | Camp4 Therapeutics GAAP EPS of -$2.65 misses by $0.77, revenue of $3.5M in-line | 3 | Seeking Alpha | ||
| 05.03. | Camp4 Therapeutics Earnings Review: Q4 Summary | 1 | Benzinga.com | ||
| 05.03. | Camp4 Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.03. | Camp4 Therapeutics Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | CAMP4 Therapeutics: CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights | 353 | GlobeNewswire (Europe) | GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance... ► Artikel lesen | |
| 05.03. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 20.02. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 16.01. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 19.12.25 | GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst | 7 | Benzinga.com | ||
| 18.12.25 | CAMP4 Therapeutics Teams With GSK On ASO Drug Candidates | 510 | AFX News | LONDON (dpa-AFX) - CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide... ► Artikel lesen | |
| 18.12.25 | CAMP4 Therapeutics prices $30 million common stock offering | 4 | Investing.com | ||
| 18.12.25 | GSK pays $17.5M to pitch its tent with CAMP4 in regulatory RNA deal | 12 | FierceBiotech | ||
| 18.12.25 | CAMP4 Therapeutics: CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock | 274 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory... ► Artikel lesen | |
| 18.12.25 | CAMP4 Therapeutics: CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries | 340 | GlobeNewswire (Europe) | Collaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront... ► Artikel lesen | |
| 18.12.25 | Camp4 Therapeutics Corp - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 33,900 | -3,32 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ARTELO BIOSCIENCES | 13,550 | +324,76 % | Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate... ► Artikel lesen | |
| ONCONETIX | 2,470 | -22,33 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS68237Q2030 Onconetix Inc. 24.03.2026 US68237Q3020 Onconetix Inc. 25.03.2026 Tausch 5:1US98386D3070 XTL Biopharmaceuticals... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,630 | +16,30 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ARCELLX | 114,63 | +0,09 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| EVOTEC | 4,304 | -1,62 % | Welche Aktie jetzt kaufen? Evotec, Nel und Lahontan Gold. | Was ist denn da bei Nel los? Innerhalb weniger Tage hat die einstige Wasserstoffhoffnung über 20 % an Wert gewonnen. Der kurzfristige Abwärtstrend wurde verlassen. Doch Analysten sehen keine Trendwende.... ► Artikel lesen | |
| BIONTECH | 75,90 | 0,00 % | Euphorie und Panik liegt dicht beisammen! BioNTech, Globex Mining, SAP | Die Finanzmärkte sind seit dem Iran-Krieg deutlich angeschlagen und nur die Hoffnung auf einen möglichen zeitnahen Frieden lässt die Märkte in dieser Woche wieder stabilisieren. Doch die Hoffnung ist... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 38,670 | -1,30 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| ZENAS BIOPHARMA | 18,060 | -18,58 % | Zenas BioPharma Prices $300M Capital Raise in Dual Offering | ||
| DAY ONE BIOPHARMACEUTICALS | 21,430 | +0,07 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| TREVI THERAPEUTICS | 11,140 | -5,63 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| VOR BIOPHARMA | 14,130 | +3,97 % | Vor Bio raises $75M in private placement led by TCGX | ||
| ALUMIS | 25,080 | -4,71 % | Alumis Inc.: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | - Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis... ► Artikel lesen | |
| MAZE THERAPEUTICS | 30,020 | -5,60 % | Maze Therapeutics: BTIG bestätigt Kaufempfehlung nach positiven Studiendaten | ||
| COGENT BIOSCIENCES | 36,695 | -0,58 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen |
Das Unternehmen CAMP4 THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.